BOSULIF (™) (bosutinib)

BOSULIF (bosutinib), indicated for, the treatment of chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) in adult patients with resistance or intolerance to prior TKI therapy, and for whom subsequent treatment with imatinib, nilotinib and dasatinib is not clinically appropriate.

To read the announcement from Pfizer regarding the Health Canada approval: Bosulif (TM) N.O.C.